Show simple item record Gonda Xénia Petschner Péter Eszlári Nóra Baksa Dániel Édes Andrea Edit Antal P Juhász Gabriella Bagdy György 2019-09-11T13:10:42Z 2019-09-11T13:10:42Z 2019
dc.identifier 85053737531
dc.identifier.citation journalVolume=194;journalTitle=PHARMACOLOGY & THERAPEUTICS;pagerange=22-43;journalAbbreviatedTitle=PHARMACOL THERAPEUT;
dc.identifier.uri doi:10.1016/j.pharmthera.2018.09.002
dc.description.abstract In spite of promising preclinical results there is a decreasing number of new registered medications in major depression. The main reason behind this fact is the lack of confirmation in clinical studies for the assumed, and in animals confirmed, therapeutic results. This suggests low predictive value of animal studies for central nervous system disorders. One solution for identifying new possible targets is the application of genetics and genomics, which may pinpoint new targets based on the effect of genetic variants in humans. The present review summarizes such research focusing on depression and its therapy. The inconsistency between most genetic studies in depression suggests, first of all, a significant role of environmental stress. Furthermore, effect of individual genes and polymorphisms is weak, therefore gene x gene interactions or complete biochemical pathways should be analyzed. Even genes encoding target proteins of currently used antidepressants remain non-significant in genome-wide case control investigations suggesting no main effect in depression, but rather an interaction with stress. The few significant genes in GWASs are related to neurogenesis, neuronal synapse, cell contact and DNA transcription and as being nonspecific for depression are difficult to harvest pharmacologically. Most candidate genes in replicable GxE interactions, on the other hand, are connected to the regulation of stress and the HPA axis and thus could serve as drug targets for a depression subgroups characterized by stress-sensitivity and anxiety while other risk polymorphisms such as those related to prominent cognitive symptoms in depression may help to identify additional subgroups and their distinct treatment. Until these new targets find their way in the therapy, the optimization of current medications can be approached by pharmacogenomics, where metabolizing enzyme polymorphisms remain prominent determinants of therapeutic success.
dc.format.extent 22-43
dc.title Genetic variants in major depressive disorder: From pathophysiology to therapy
dc.type Journal Article 2019-02-26T07:32:29Z
dc.language.rfc3066 en
dc.rights.holder NULL
dc.identifier.mtmt 3413351
dc.identifier.wos 000457951500002
dc.identifier.pubmed 30189291
dc.contributor.department SE/GYTK/GYHATAS/MTA-SE Neuropszichofarmakológiai és Neurokémiai Kutatócsoport
dc.contributor.department SE/AOK/K/Pszichiátriai és Pszichoterápiás Klinika
dc.contributor.department SE/GYTK/GYHATAS/NAP-2-SE Új Antidepresszív Gyógyszercélpont Kutatócsoport
dc.contributor.department SE/GYTK/Gyógyszerhatástani Intézet
dc.contributor.department SE/GYTK/GYHATAS/SE-NAP 2 Genetikai Agyi Képalkotó Migrén Kutatócsoport
dc.contributor.institution Semmelweis Egyetem
dc.mtmt.swordnote Xenia Gonda and Peter Petschner authors contributed equally to the manuscript.

Files in this item



This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account